Gilead Sciences CFO Robin L. Washington Sells 4,304 Shares (GILD)
Gilead Sciences (NASDAQ:GILD) CFO Robin L. Washington unloaded 4,304 shares of the company’s stock on the open market in a transaction dated Monday, August 25th. The stock was sold at an average price of $105.87, for a total value of $455,664.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Gilead Sciences (NASDAQ:GILD) traded up 1.07% during mid-day trading on Wednesday, hitting $107.41. 16,186,717 shares of the company’s stock traded hands. Gilead Sciences has a 52 week low of $58.50 and a 52 week high of $108.72. The stock has a 50-day moving average of $93.28 and a 200-day moving average of $82.43. The company has a market cap of $162.4 billion and a P/E ratio of 24.08. Gilead Sciences also was the target of unusually large options trading activity on Tuesday. Investors acquired 23,938 put options on the company. This represents an increase of approximately 116% compared to the typical daily volume of 11,107 put options.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, July 23rd. The company reported $2.36 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.73 by $0.63. The company had revenue of $6.53 billion for the quarter, compared to the consensus estimate of $5.68 billion. During the same quarter in the previous year, the company posted $0.50 earnings per share. The company’s revenue for the quarter was up 136.1% on a year-over-year basis. Analysts expect that Gilead Sciences will post $8.00 EPS for the current fiscal year.
A number of research firms have recently commented on GILD. Analysts at RBC Capital raised their price target on shares of Gilead Sciences from $102.00 to $115.00 in a research note on Friday, August 22nd. They now have an “outperform” rating on the stock. Separately, analysts at Cowen and Company raised their price target on shares of Gilead Sciences from $95.00 to $105.00 in a research note on Friday, August 15th. They now have an “outperform” rating on the stock. One analyst has rated the stock with a hold rating and twenty-one have assigned a buy rating to the company. Gilead Sciences presently has an average rating of “Buy” and an average price target of $105.55.
Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.